Prognostic models for selecting patients with acute pulmonary embolism for initial outpatient therapy

Current Opinion in Pulmonary Medicine

Volumn 14, Issue 5, 2008, Pages 414-421

  Jiménez, David ^a,c   Yusen, Roger D ^b  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Clinical scores; Outpatient treatment; Prognosis; Pulmonary embolism

Indexed keywords

TROPONIN;

ACUTE DISEASE; BLEEDING; CONTROLLED STUDY; DEATH; EMERGENCY WARD; EXTERNAL VALIDITY; FOLLOW UP; HUMAN; LUNG EMBOLISM; MEDICAL DECISION MAKING; MORTALITY; OUTPATIENT CARE; PATIENT SELECTION; PREDICTION; PROGNOSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; VENOUS THROMBOEMBOLISM; DECISION SUPPORT SYSTEM; HOSPITALIZATION; OUTPATIENT;

ACUTE DISEASE; DECISION SUPPORT TECHNIQUES; HUMANS; OUTPATIENTS; PATIENT SELECTION; PROGNOSIS; PULMONARY EMBOLISM; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX;

EID: 53149113830     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e3283043e44     Document Type: Review

References (36)

1. Spencer FA, Gore JM, Lessard D, et al. Patient outcomes after deep vein thrombosis and pulmonary embolism. Arch Intern Med 2008; 168:425-430.
2. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999; 353:1386-1389.
3. Laporte S, Mismetti P, Décousus H, et al. Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism. Findings from the Registro Informatizado de la Enfermedad Tromboembolica Venosa (RIETE) Registry. Circulation 2008; 117:1711-1716.
4. Büller HR, Davidson BL, Decousus H, et al. Subcutaneous fondaparinux versus unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003; 349:1695-1702.
5. Van Gogh Investigators. Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med 2007; 13:1094-1104.
6. British Thoracic Society Standards of Care Committee Pulmonary Embolism Guideline Development Group. British Thoracic Society guidelines for the management of suspected acute pulmonary embolism. Thorax 2003; 58:470-483.
7. Wells PS, Kovacs MJ, Bormanis J, et al. Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low-molecular-weight heparin: a comparison of patient self-injection with homecare injection. Arch Intern Med 1998; 158:1809-1812.
8. Kovacs MJ, Anderson D, Morrow B, et al. Outpatient treatment of pulmonary embolism with dalteparin. Thromb Haemost 2000; 83:209-211.
9. Beer JH, Burger M, Gretener S, et al. Outpatient treatment of pulmonary embolism is feasible and safe in a substantial proportion of patients. J Thromb Haemost 2003; 1:186-187.
10. Rhodes S, Bond S, Green S, et al. Outpatient management of pulmonary embolism: results from the national multicentre PE study [abstract]. Blood 2005; 106:911.
11. Wells PS, Anderson DR, Rodger MA, et al. A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolism. Arch Intern Med 2005; 165:733-738.
12. Olsson CG, Bitzen U, Olson B, et al. Outpatient tinzaparin therapy in pulmonary embolism quantified with ventilation/perfusion scintigraphy. Med Sci Monit 2006; 12:9-13.
13. Aujesky D, Smith KJ, Cornuz J, Roberts MS. Cost-effectiveness of low-molecular-weight heparin for treatment of pulmonary embolism. Chest 2005; 128:1601-1610.
14. Heit J, Silverstein M, Mohr D, et al. Predictors of survival after deep vein thrombosis and pulmonary embolism. Arch Intern Med 1999; 159:445-453.
15. Grifoni S, Olivotto I, Cecchini P, et al. Short-term clinical outcome of patients with acute pulmonary embolism, normal blood pressure, and echocardiographic right ventricular dysfunction. Circulation 2000; 101:237-247.
16. Kasper W, Konstantinides S, Geibel A, et al. Prognostic significance of right ventricular afterload stress detected by echocardiography in patients with clinically suspected pulmonary embolism. Heart 1997; 77:346-349.
17. Becattini C, Bedovati MC, Agnelli G. Prognostic value of troponins in acute pulmonary embolism. A meta-analysis. Circulation 2007; 116:427-433.
18. Grau E, Tenias JM, Soto MJ, et al. D-dimer levels correlate with mortality in patients with acute pulmonary embolism: findings from the RIETE Registry. Crit Care Med 2007; 35:1937-1941.
19. Binder L, Pieske B, Olschewski M, et al. N-terminal pro-brain natriuretic peptide or troponin testing followed by echocardiography for risk stratification of acute pulmonary embolism. Circulation 2005; 112:1573-1579.
20. Kucher N, Printzen G, Doernhoefer T, et al. Low pro-brain natriuretic peptide levels predict benign clinical outcome in acute pulmonary embolism. Circulation 2003; 107:1576-1578.
21. Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996; 334:677-681.
22. Koopman MM, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med 1996; 334:682-687.
23. Yusen RD, Haraden BM, Gage BF, et al. Criteria for outpatient management of proximal lower deep venous thrombosis. Chest 1999; 115:972-979.
24. Wicki J, Perrier A, Perneger TV, et al. Predicting adverse outcome in patients with acute pulmonary embolism: a risk score. Thromb Haemost 2000; 84:548-552.
25. Aujesky D, Obrosky DS, Stone RA, et al. Derivation and validation of a prognostic model for pulmonary embolism. Am J Respir Crit Care Med 2005; 172:1041-1046.
26. Uresandi F, Otero R, Cayuela A, et al. A clinical prediction rule for identifying short-term risk of adverse events in patients with pulmonary thromboembolism. Arch Bronconeumol 2007; 43:617-622.
27. Davies CWH, Wimperis J, Green ES, et al. Early discharge of patients with pulmonary embolism: a two-phase observational study. Eur Respir J 2007; 30:708-714.
28. Murugappan M, Johnson JA, Gage BF, et al. HOme Management Exclusion (HOME) criteria for initial treatment of acute pulmonary embolism. Am J Respir Crit Care Med 2008; 177:A182.
29. Nendaz MR, Bandelier P, Aujesky D, et al. Validation of a risk score identifying patients with acute pulmonary embolism, who are at low risk of clinical adverse outcome. Thromb Haemost 2004; 91:1232-1236.
30. Aujesky D, Roy PM, Le Manach CP, et al. Validation of a model to predict adverse outcomes in patients with pulmonary embolism. Eur Heart J 2006; 27:476-481.
31. Aujesky D, Perrier A, Roy PM, et al. Validation of a clinical prognostic model to identify low-risk patients with pulmonary embolism. J Intern Med 2007; 261:597-604.
32. Jiménez D, Yusen RD, Otero R, et al. Prognostic models for selecting patients with acute pulmonary embolism for initial outpatient therapy. Chest 2007; 132:24-30.
33. Otero R, Jiménez D, On behalf of the Cooperative Study for the Ambulatory Treatment of Patients with Pulmonary Embolism Research Study Group. Pulmonary embolism at home. Eur Respir J 2008; 31:686-687.
34. Scridon T, Scridon C, Skali H, et al. Prognostic significance of troponin elevation and right ventricular enlargement in acute pulmonary embolism. Am J Cardiol 2005; 96:303-305.
35. Jiménez D, DíazG, Molina J, et al.Troponin I and risk stratification of patients with acute non massive pulmonary embolism. Eur Respir J 2008; 31:847-853.
36. Kucher N, Goldhaber SZ. Cardiac biomarkers for risk stratification of patients with acute pulmonary embolism. Circulation 2003; 108:2191-2194.